Prosecution Insights
Last updated: April 19, 2026
Application No. 16/817,458

CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF

Final Rejection §112
Filed
Mar 12, 2020
Examiner
GROSS, CHRISTOPHER M
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regeneron Pharmaceuticals, Inc.
OA Round
6 (Final)
63%
Grant Probability
Moderate
7-8
OA Rounds
4y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
410 granted / 651 resolved
+3.0% vs TC avg
Strong +41% interview lift
Without
With
+41.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
37 currently pending
Career history
688
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
31.9%
-8.1% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
23.1%
-16.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 651 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Responsive to communications entered 23SEP2025 Claims pending: 1-4,6,9-10,29-82,95-119 Claims withdrawn: 29-80,95-116 Claims under consideration: 1-4,6,9-10,81,82,117-119 Priority This application has a filing date of 03/12/2020 and has PRO 62/933,319 filed 11/08/2019 and PRO 62/817,020 filed 03/12/2019. Withdrawn Objection(s) and/or Rejection(s) All rejections from the previous action are hereby withdrawn in light of Applicant’s amendments and corresponding persuasive arguments. New Claim Rejection(s) – 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4,6,9-10,81,82,117-119 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection concerns new matter. Claim 1 has introduced the limitation of a peptide 10 to 30 amino acids in length and the current remarks urge support therefor may be found at page 11 lines 14-19 and page 50 lines 16-19 of the original specification. In reviewing the passages, however the examiner only finds description of a capture agent with a “first” epitope that may be 10 or 30 residues. Further page 50 lines 16-19, in context with p 50 line 10-15, describes such capture agent as having a first ligand that binds CD8 and is covalently connected to a second epitope through a linker. The passages do not describe a reporter; alkyne, azide or the lack of a phosphorylated amino acid as recited in amended claim 1. As such, the specification as originally filed provided no implicit or explicit support for a lone 10 to 30 residue peptide with an epitope of any target, much less a peptide bearing a reporter, an alkyne or azide amino acid and lacking a phosphorylated amino acid, as is now claimed and the remarks do not point to where newly presented subject matter may be found in the priority documents. Applicants are reminded that it is their burden to show where the specification supports any amendments to the disclosure. See MPEP 714.02, paragraph 5, last sentence and also MPEP 2163.06 I. MPEP 2163.06 notes “If new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981).” MPEP 2163.02 teaches that “Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application. MPEP 2163.06 further notes “When an amendment is filed in reply to an objection or rejection based on 35 U.S.C. 112, first paragraph, a study of the entire application is often necessary to determine whether or not “new matter” is involved. Applicant should therefore specifically point out the support for any amendments made to the disclosure. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER M GROSS whose telephone number is (571)272-4446. The examiner can normally be reached M-F 10-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached on (571)272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTOPHER M GROSS/ Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Mar 12, 2020
Application Filed
Jul 02, 2021
Non-Final Rejection — §112
Jan 07, 2022
Response Filed
Apr 29, 2022
Final Rejection — §112
Nov 04, 2022
Notice of Allowance
Dec 15, 2022
Response after Non-Final Action
Dec 28, 2022
Response after Non-Final Action
Jan 09, 2023
Request for Continued Examination
Jan 10, 2023
Response after Non-Final Action
Feb 25, 2023
Non-Final Rejection — §112
Sep 05, 2023
Response Filed
Nov 30, 2023
Final Rejection — §112
Jun 06, 2024
Notice of Allowance
Jun 06, 2024
Response after Non-Final Action
Jan 06, 2025
Request for Continued Examination
Jan 13, 2025
Response after Non-Final Action
Mar 20, 2025
Non-Final Rejection — §112
Aug 25, 2025
Interview Requested
Sep 10, 2025
Examiner Interview Summary
Sep 23, 2025
Response Filed
Jan 11, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12577555
SCREENING METHOD FOR TELOMERASE REVERSE TRANSCRIPTASE (TERT) PHOSPHORYLATION INHIBITORS
2y 5m to grant Granted Mar 17, 2026
Patent 12558350
COMPOSITIONS AND METHODS FOR TREATMENT
2y 5m to grant Granted Feb 24, 2026
Patent 12553892
ASSAYS FOR ANTIMICROBIAL ACTIVITY AND APPLICATIONS THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12553074
PROCESSES AND SYSTEMS FOR PREPARATION OF NUCLEIC ACID SEQUENCING LIBRARIES AND LIBRARIES PREPARED USING SAME
2y 5m to grant Granted Feb 17, 2026
Patent 12540318
NUCLEIC ACIDS ENCODING CHIMERIC POLYPEPTIDES FOR LIBRARY SCREENING
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+41.2%)
4y 1m
Median Time to Grant
High
PTA Risk
Based on 651 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month